Human Immunodeficiency Virus Preexposure Prophylaxis: A Quick Guide for Primary Care Practice

摘要

Human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) is when HIV-negative persons use antiretroviral medication to prevent HIV acquisition. It is up to 96% efficacious. Patients at risk for HIV warrant PrEP, and contraindications include being HIV positive and an estimated glomerular filtration rate (eGFR) < 60 mL/min. PrEP should be prescribed as 1 daily oral tablet of emtricitabine/tenofovir disoproxil fumarate, and repeat HIV and creatinine testing should occur after 1 month of medication use and then every 3 months. Patients who become HIV positive should be referred for care; those with an eGFR that decreases < 60 mL/min should be discontinued and monitored. Marked changes in eGFR or creatinine warrant monitoring. (C) 2019 Elsevier Inc. All rights reserved.